Sodium-glucose cotransporter inhibitors (SGLTi) as an adjunctive to insulin therapy may offer cardiometabolic and renal benefits in adults with type 1 diabetes (T1D). Their effective use depends on patient selection, education, and ketone monitoring to prevent... ...

请注册登录后继续浏览